Malignancies of the head and neck: The role for molecular targeted agents

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 2, 2007, Pages 207-217

  Agulnik, Mark ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Head and neck neoplasm; Investigational therapy; Nasopharyngeal neoplasm; Salivary gland neoplasm

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; METHOTREXATE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATINUM COMPLEX; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; MONOTHERAPY; NASOPHARYNX CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SALIVARY GLAND CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846677634     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.2.207     Document Type: Review

References (80)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55:10-30.
2. WOODBURN JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. (1999) 82:241-250.
3. MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy. Oncogene (2000) 19:6550-6565.
4. SCHLESSINGER J: Cell signaling by receptor tyrosine kinascs. Cell (2000) 103:211-225.
5. YARDEN Y: The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur. J. Cancer (2001) 37(Suppl. 4):S3-S8.
6. RUBIN GRANDIS J, MELHEM MF, BARNES EL, TWEARDY DJ: Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (1996) 78:1284-1292.
7. RUBIN GRANDIS J, MELHEM MF, GOODING WE et al.: Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. (1998) 90:824-832.
8. SANTINI J, FORMENTO JL, FRANCOUAL M et al.: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck (1991) 13:132-139.
9. SHIN DM, RO JY, HONG WK, HITTELMAN WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. (1994) 54:3153-3159.
10. BEI R, BUDILLON A, MASUELLI L et al.: Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J. Pathol. (2004) 204:317-325.
11. GRANDIS JR, TWEARDY DJ: Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. (1993) 53:3579-3584.
12. ONGKEKO WM, ALTUNA X, WEISMAN RA, WANG-RODRIGUEZ J: Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am. J. Clin. Pathol. (2005) 124:71-76.
13. COHEN EE, KANE MA, LIST MA et al.: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. (2005) 11:8418-8424.
14. COHEN EE, ROSEN F, STADLER WM et al.: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2003) 21:1980-1987.
15. WHEELER RH, JONES D, SHARMA P et al.: Clinical and molecular Phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). 2005 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2005) 23:5531.
16. SOULIERES D, SENZER NN, VOKES EE et al.: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. (2004) 22:77-85.
17. BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. (2000) 18:904-914.
18. SHIN DM, DONATO NJ, PEREZ-SOLER R et al.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. (2001) 7:1204-1213.
19. TRIGO JM, HITT R, KORALEWSKI P et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metasmtic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. 2004 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2004) 22:5502.
20. BASELGA J, TRIGO JM, BOURHIS J et al.: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2005) 23:5568-5577.
21. HERBST RS, ARQUETTE M, SHIN DM et al.: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2005) 23:5578-5587.
22. BONNER JA, HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354:567-578.
23. BURTNESS B, GOLDWASSER MA, FLOOD W, MATFAR B, FORASTIERE AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. (2005) 23:8646-8654.
24. AGULNIK M, DA CUNHA-SANTOS G, HEDLEY D et al.: Pharmacodynamic Studies of erlotinib in tumor and skin tissue samples of patients (Pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Clin. Cancer Res. (2005) 11:167 (B158).
25. ABIDOYE AA, COHEN EE, WONG SJ et al.: A Phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). 2006ASC0 Ann. Meet. Proc. J. Clin. Oncol. (2006) 24:5568.
26. HARRINGTON KJ, BOURHIS J, NUTTING CM et al.: A Phase I, open-label study of lapatinib plus chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. 2006 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2006)24:5553.
27. CHEN E, WINQUIST E, AGULNIK M et al.: A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). Eur. J. Cancer (2005) 3:a297.
28. VOKES E, COHEN EE, MAUER AM et al.: A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). 2005 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2005) 23:5504.
29. FANDI A, ALTUN M, AZLI N, ARMAND JP, CVITKOVIC E: Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin. Oncol. (1994) 21:382-397.
30. MA BB, TANNOCK IF, POND GR, EDMONDS MR, SIU LL: Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer (2002) 95:2516-2523.
31. FANDI A, BACHOUCHI M, AZLI N et al.: Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J. Clin. Oncol. (2000) 18:1324-1330.
32. CHUA DTT, MA J, SHAM JST: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two Phase III trials. J. Clin. Oncol. (2004) 22S:5524a.
33. LEONG JL, LOH KS, PUTTI TC, GOH BC, TAN LK: Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope (2004) 114:153-157.
34. CHAN ATC, HSU MM, GOH BC et al.: A Phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2003) 22:497.
35. CHAN AT, MA BB, HUI EP et al.: Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC). 2006 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2006) 24:15509.
36. GUANG-WU H, SUNAGAWA M, JIE-EN L et al.: The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope (2000) 110:2066-2069.
37. BAR-SELA G, KUTEN A, BEN-ELIEZER S, GOV-ARI E, BEN-IZHAK O: Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod. Pathol. (2003) 16:1035-1040.
38. MA BB, POON TC, TO KF et al.: Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck (2003) 25:864-872.
39. YAN J, FANG Y, HUANG BJ et al.: Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. Cancer Genet. Cytogenet. (2002) 132:116-119.
40. HOCWALD E, KORKMAZ H, YOO GH et al.: Prognostic factors in major salivary gland cancer. Laryngoscope (2001) 111:1434-1439.
41. SPEIGHT PM, BARRETT AW: Salivary gland tumours. Oral Dis. (2002) 8:229-240.
42. SPIRO RH: Management of malignant tumors of the salivary glands. Oncology (Williston Park) (1998) 12:671-680; discussion 683.
43. LAURIE SA, LICITRA L: Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol. (2006) 24:2673-2678.
44. PENNER CR, FOLPE AL, BUDNICK SD: C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod. Pathol. (2002) 15:687-691.
45. HOLST VA, MARSHALL CE, MOSKALUK CA, FRIERSON HF Jr: KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod. Pathol. (1999) 12:956-960.
46. JENG YM, LIN CY, HSU HC: Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. (2000) 154:107-111.
47. HOTTE SJ, WINQUIST EW, LAMONT E et al.: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II consortium study. J. Clin. Oncol. (2005) 23:585-590.
48. SLEVIN MJ, MAIS KL, BRUCE I et al.: Imatinib with cisplatin in recurrent and/or metastatic salivary adenoidcystic carcinoma - response assessed by FDG-PET scanning. 2004 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2004) 22:5604.
49. BARNES L, RAO U, CONTIS L et al.: Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg. Oral Med. Oral Pathol. (1994) 78:74-80.
50. CHEN CH, LI BY, WAN JT et al.: Expression of epidermal growth factor in salivary adenoid cystic carcinoma. Proc. Natl Sci. Counc. Repub. China B (2001) 25:90-96.
51. CHO KJ, KIM JY, LEE SS, OH KK: Mucoepidermoid carcinoma of the salivary gland-a clinico-pathologic and immunohistochemical study for c-erbB-2 oncoprotein. J. Korean Med. Sci. (1997) 12:499-504.
52. CHO KJ, LEE SS, LEE YS: Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck (1999) 21:414-419.
53. DORI S, VERED M, DAVID R, BUCHNER A: HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J. Oral Pathol. Med. (2002) 31:463-467.
54. ETGES A, PINTO DS Jr, KOWALSKI LP, SOARES FA, ARAUJO VC: Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J. Clin. Pathol. (2003) 56:914-918.
55. FAN CY, MELHEM MF, HOSAL AS, GRANDIS JR, BARNES EL: Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor α in salivary duct carcinoma. Arch. Otolaryngol. Head Neck Surg. (2001) 127:1075-1079.
56. FELIX A, EL-NAGGAR AK, PRESS MF et al.: Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum. Pathol. (1996) 27:561-566.
57. GLISSON B, COLEVAS AD, HADDAD R et al.: HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin. Cancer Res. (2004) 10:944-946.
58. KARJA V, SYRJANEN S, KATAJA V, SYRJANEN K: c-erbB-2 oncogene expression in salivary gland tumours. ORL J. Otorhinolaryngol. Relat. Spec. (1994) 56:206-212.
59. KERNOHAN NM, BLESSING K, KING G, CORBETT IP, MILLER ID: Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J. Pathol. (1991) 163:77-80.
60. MARTINEZ-BARBA E, CORTES-GUARDIOLA JA, MINGUELA-PURAS A et al.: Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J. Craniomaxillofac. Surg. (1997) 25:328-334.
61. PRESS MF, PIKE MC, HUNG G et al.: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. (1994) 54:5675-5682.
62. SHINTANI S, FUNAYAMA T, YOSHIHAMA Y et al.: Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anti-Cancer Res. (1995) 15:2623-2626.
63. SKALOVA A, STAREK, KUCEROVA V, SZEPE P, PLANK L: Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol. Res. Pract. (2001) 197:621-626.
64. SKALOVA A, STAREK I, VANECEK T et al.: Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology (2003) 42:348-356.
65. SUGANO S, MUKAI K, TSUDA H et al.: Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope (1992) 102: 923-927.
66. VERED M, BRAUNSTEIN E, BUCHNER A: Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck (2002) 24:632-636.
67. YAMADA K, IWAI K, OKADA Y, MORI M: Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch. A Pathol. Anat. Histopathol. (1989) 415:523-531.
68. AGULNIK M, COHEN EE, COHEN RB et al.: A Phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). 2006 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2006) 24:5566.
69. AGULNIK M, COHEN EE, COHEN RB et al.: A multicenter Phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Ann. Oncol. (2006) 17:ix 179.
70. GIANNONI C, EL-NAGGAR AK, ORDONEZ NG et al.: c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol. Head Neck Surg. (1995) 112:391-398.
71. NAGLERRM, KERNERH, BEN-ELIEZER S, MINKOV I, BEN-ITZHAK O: Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. Oncology (2003) 64:389-398.
72. STENMAN G, SANDROS J, NORDKVIST A, MARK J, SAHLIN P: Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer (1991) 3:128-135.
73. CHO KJ, EL-NAGGAR AK, ORDONEZ NG et al.: Epithelial-myoepithelial carcinoma of salivary glands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and HER-2/neu oncogene. Am. J. Clin. Pathol. (1995) 103:432-437.
74. HADDAD R, COLEVAS AD, KRANE JF et al.: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A Phase II study. Oral Oncol. (2003) 39:724-727.
75. LICITRA LF, LOCATI LD, POTEPAN P et al.: Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional Phase II study. 2006 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2006) 24:5547.
76. GLISSON BS, BLUMENSCHEIN G, FRANCISCO M et al.: Phase II trial of gefitinib in patients with incurable salivary gland cancer. 2005 ASCO Ann. Meet. Proc. J. Clin. Oncol. (2005) 23:5532.
77. DOI R, KURATATE I, OKAMOTO E, RYOKE K, ITO H: Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas. J. Oral Pathol. Med. (1999) 28:259-263.
78. LIM JJ, KANG S, LEE MR et al.: Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J. Oral Pathol. Med. (2003) 32:552-561.
79. RUGO HS, HERBST RS, LIU G et al.: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. (2005) 23:5474-5483.
80. STRAATHOF KC, BOLLARD CM, POPAT U et al.: Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood (2005) 105:1898-1904.